Anergis Overview

  • Founded
  • 2001

Founded
  • Status
  • Out of Business

  • Employees
  • 11

Employees
  • Latest Deal Type
  • Liquidation

Anergis General Information

Description

Developer of disease-modifying allergy immunotherapy intended to improve the medical treatment of patients suffering from allergies. The company's immunotherapy is based on a proprietary allergy vaccines targeting commercially attractive indications, enabling patients to get a long-term cure for allergies and reduce the treatment time.

Contact Information

Website
www.anergis.ch
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Biopôle Building SC-A
  • Route de la Corniche 4
  • 1066 Epalinges
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Anergis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Bankruptcy: Liquidation 01-Aug-2021 000.00 Completed Bankruptcy: Liquidation
4. Later Stage VC (Series B) 04-Apr-2016 000.00 000.00 000.00 Completed Generating Revenue
3. Grant 27-Sep-2013 000.00 000.00 Completed Generating Revenue
2. Later Stage VC (Series A) 28-Mar-2011 $19.6M $22.8M 000.00 Completed Generating Revenue
1. Seed Round $3.26M $3.26M Completed Startup
To view Anergis’s complete valuation and funding history, request access »

Anergis Patents

Anergis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20150050301-A1 Contiguous overlapping peptides for treatment of house dust mites allergy Inactive 06-Jun-2013 000000000000 0
JP-6640818-B2 Consecutive overlapping peptides for the treatment of house dust mite allergy Active 06-Jun-2013 000000000000
JP-2016523231-A Consecutive overlapping peptides for the treatment of house dust mite allergy Active 06-Jun-2013 000000000000
JP-2018058856-A Contiguous overlapping peptides for treating house dust mite allergy Active 06-Jun-2013 000000000000
JP-6300907-B2 Consecutive overlapping peptides for the treatment of house dust mite allergy Active 06-Jun-2013 C07K14/43531
To view Anergis’s complete patent history, request access »

Anergis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial